[Ann Indian Acad Neurol](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445212/). 2015 Apr-Jun; 18(2): 256–257.

doi:  [10.4103/0972-2327.150620](https://dx.doi.org/10.4103%2F0972-2327.150620)

PMCID: PMC4445212

PMID: [26019434](https://www.ncbi.nlm.nih.gov/pubmed/26019434)

Refractory status epilepticus from NMDA receptor encephalitis successfully treated with an adjunctive ketogenic diet

[Syed Amer](https://www.ncbi.nlm.nih.gov/pubmed/?term=Amer%20S%5BAuthor%5D&cauthor=true&cauthor_uid=26019434), [Parth Shah](https://www.ncbi.nlm.nih.gov/pubmed/?term=Shah%20P%5BAuthor%5D&cauthor=true&cauthor_uid=26019434),1 and [Vishnu Kommineni](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kommineni%20V%5BAuthor%5D&cauthor=true&cauthor_uid=26019434)1

[Author information ►](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445212/) [Copyright and License information ►](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445212/) [Disclaimer](https://www.ncbi.nlm.nih.gov/pmc/about/disclaimer/)

This article has been [cited by](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445212/citedby/) other articles in PMC.

Sir,

N-methyl D-aspartate receptor encephalitis (NMDARE) is characterized by the presence of NMDAR antibodies in the CSF, and it can progress to psychosis and refractory status epilepticus (RSE). We report a case of the use of a ketogenic diet (KD) as an adjunct in RSE from NMDARE.

A healthy 21-year-old female presented to the ED with symptoms that progressed from depression, headaches, and nausea to word-finding difficulties, psychosis, and seizures. She developed SE and was intubated. A comprehensive evaluation was unremarkable, and she was transferred to our institution on hospital day 11 where an electro-encephalogram (EEG) revealed RSE. The NMDAR antibody was detected in her CSF. A thorough investigation was negative for any tumor. Despite corticosteroids, plasmapheresis, IV Ig in addition to 5 anticonvulsant medications and propofol, continuous EEG showed RSE. Ketosis was achieved after a KD (ratio of fat: Combined carbohydrate and protein of 4:1) was started (day 21). Her continuous EEG showed a significant decrease in her seizures within 2 weeks (day 35). She was weaned off mechanical ventilation and discharged to a long-term care facility on 3 anticonvulsant medications, mycophenolate mofetil, and on a KD.

Most patients with NMDARE develop a multistage illness that progresses to psychosis, memory deficits, RSE, and into a state of unresponsiveness with catatonic features.[[1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445212/" \l "ref1)] Management of NMDARE should initially focus on immunotherapy and the detection and removal of the tumor.[[2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445212/" \l "ref2),[3](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445212/" \l "ref3)] Most patients receive corticosteroids, PLEX, or IV Ig as first-line immunotherapy. Additional treatment with second-line cyclophosphamide or rituximab is sometimes needed. Our patient continued to deteriorate despite these therapies. A KD, by reducing the firing of central neurons by opening K ATP channels[[4](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445212/" \l "ref4)], is a very effective adjunct to antiepileptics in patients with refractory epilepsy. Side effects of KD[[5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445212/" \l "ref5)] are usually mild, predictable, and preventable, and rarely lead to diet discontinuation. Important ones include constipation, acidosis, dyslipidemia, kidney stones, and bone fractures.

To our knowledge, this is the first case report of initiating a KD as an adjunct in RSE from NMDARE.

[Go to:](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445212/)

References

1. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158385/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21163445)]

2. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–8.[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607118/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18851928)]

3. Niehusmann P, Dalmau J, Rudlowski C, Vincent A, Elger CE, Rossi JE, et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol. 2009;66:458–64. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19364930)]

4. Ma W, Berg J, Yellen G. Ketogenic diet metabolites reduce firing in central neurons by opening K (ATP) channels. J Neurosci. 2007;27:3618–25. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17409226)]

5. Kang HC, Chung DE, Kim DW, Kim HD. Early-and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia. 2004;45:1116–23. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15329077)]